FSD PHARMA (HUGE)
(Delayed Data from NSDQ)
$0.20 USD
+0.11 (120.75%)
Updated Aug 9, 2024 04:00 PM ET
Pre-Market: $0.19 -0.01 (-5.00%) 8:16 AM ET
3-Hold of 5 3
C Value B Growth NA Momentum NA VGM
Balance Sheet
Fiscal Year End for FSD PHARMA falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 17 | 35 | 18 | 6 |
Receivables | 7 | 0 | 1 | 0 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 1 |
Other Current Assets | 0 | 0 | 10 | 9 | 0 |
Total Current Assets | 11 | 18 | 46 | 27 | 9 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 9 |
Investments & Advances | 0 | 1 | 1 | 2 | 9 |
Other Non-Current Assets | 1 | 7 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 5 | 12 | 16 | 13 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 17 | 38 | 63 | 42 | 43 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 1 |
Accounts Payable | 4 | 7 | 8 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 1 | 2 |
Total Current Liabilities | 5 | 8 | 9 | 6 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5 | 8 | 9 | 6 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 138 | 143 | 152 | 103 | 74 |
Capital Surplus | 30 | 29 | 23 | 19 | 17 |
Retained Earnings | -158 | -144 | -126 | -91 | -59 |
Other Equity | 3 | 3 | 5 | 5 | 4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 13 | 31 | 54 | 36 | 36 |
Total Liabilities & Shareholder's Equity | 17 | 38 | 63 | 42 | 43 |
Total Common Equity | 13 | 31 | 54 | 36 | 36 |
Shares Outstanding | 39.30 | 38.50 | 40.40 | 19.10 | 7.00 |
Book Value Per Share | 0.33 | 0.79 | 1.34 | 1.90 | 5.19 |
Fiscal Year End for FSD PHARMA falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 2 | 4 | 4 | 6 |
Receivables | NA | 7 | 7 | 4 | 3 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 0 | 1 |
Total Current Assets | NA | 9 | 11 | 9 | 9 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 1 |
Other Non-Current Assets | NA | 1 | 1 | 4 | 6 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 5 | 5 | 5 | 6 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 15 | 17 | 19 | 21 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 1 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 4 | 4 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 4 | 5 | 4 | 6 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 4 | 5 | 4 | 6 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 139 | 138 | 138 | 137 |
Capital Surplus | NA | 31 | 30 | 30 | 30 |
Retained Earnings | NA | -160 | -158 | -157 | -155 |
Other Equity | NA | 2 | 3 | 3 | 4 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 12 | 13 | 15 | 16 |
Total Liabilities & Shareholder's Equity | NA | 15 | 17 | 19 | 21 |
Total Common Equity | 0 | 12 | 13 | 15 | 16 |
Shares Outstanding | 40.10 | 40.10 | 39.30 | 39.30 | 39.00 |
Book Value Per Share | 0.00 | 0.29 | 0.33 | 0.38 | 0.40 |